Compare with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

KRSNAA DIAGNOSTICS vs VIJAYA DIAGNOSTIC - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    KRSNAA DIAGNOSTICS VIJAYA DIAGNOSTIC KRSNAA DIAGNOSTICS/
VIJAYA DIAGNOSTIC
 
P/E (TTM) x - - - View Chart
P/BV x 9.2 14.7 62.3% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 KRSNAA DIAGNOSTICS   VIJAYA DIAGNOSTIC
EQUITY SHARE DATA
    KRSNAA DIAGNOSTICS
Mar-21
VIJAYA DIAGNOSTIC
Mar-21
KRSNAA DIAGNOSTICS/
VIJAYA DIAGNOSTIC
5-Yr Chart
Click to enlarge
High RsNANA-   
Low RsNANA-   
Sales per share (Unadj.) Rs998.883.1 1,201.5%  
Earnings per share (Unadj.) Rs284.518.7 1,518.5%  
Cash flow per share (Unadj.) Rs342.129.9 1,145.4%  
Dividends per share (Unadj.) Rs00-  
Avg Dividend yield %NMNM- 
Book value per share (Unadj.) Rs355.579.2 448.7%  
Shares outstanding (eoy) m6.5045.32 14.3%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x00-   
Avg P/E ratio x00-  
P/CF ratio (eoy) x00-  
Price / Book Value ratio x00-  
Dividend payout %00-   
Avg Mkt Cap Rs m00-   
No. of employees `000NANA-   
Total wages/salary Rs m296574 51.5%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m6,4923,767 172.3%  
Other income Rs m122118 103.3%   
Total revenues Rs m6,6153,886 170.2%   
Gross profit Rs m3,4661,660 208.8%  
Depreciation Rs m374505 74.2%   
Interest Rs m259152 170.1%   
Profit before tax Rs m2,9551,121 263.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,105272 406.1%   
Profit after tax Rs m1,849849 217.8%  
Gross profit margin %53.444.1 121.2%  
Effective tax rate %37.424.3 154.1%   
Net profit margin %28.522.5 126.4%  
BALANCE SHEET DATA
Current assets Rs m2,4812,388 103.9%   
Current liabilities Rs m1,838440 417.9%   
Net working cap to sales %9.951.7 19.2%  
Current ratio x1.45.4 24.9%  
Inventory Days Days2545 55.0%  
Debtors Days Days416 656.3%  
Net fixed assets Rs m3,5642,961 120.4%   
Share capital Rs m2,48945 5,491.7%   
"Free" reserves Rs m-1783,545 -5.0%   
Net worth Rs m2,3103,590 64.4%   
Long term debt Rs m1,68033 5,128.4%   
Total assets Rs m6,0455,348 113.0%  
Interest coverage x12.48.4 148.3%   
Debt to equity ratio x0.70 7,968.6%  
Sales to assets ratio x1.10.7 152.5%   
Return on assets %34.918.7 186.3%  
Return on equity %80.023.7 338.4%  
Return on capital %80.535.2 229.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m00-   
Fx outflow Rs m00-   
Net fx Rs m00-   
CASH FLOW
From Operations Rs m1,0261,296 79.1%  
From Investments Rs m-611-1,298 47.1%  
From Financial Activity Rs m308-488 -63.2%  
Net Cashflow Rs m723-489 -147.8%  

Share Holding

Indian Promoters % 27.4 54.8 50.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 34.6 41.3 83.6%  
FIIs % 4.4 16.7 26.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 72.6 45.2 160.6%  
Shareholders   75,065 82,139 91.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare KRSNAA DIAGNOSTICS With:   FORTIS HEALTHCARE    INDRAPRASTHA MEDICAL    THYROCARE TECHNOLOGIES    DR. LAL PATHLABS    KOVAI MEDICAL    



Today's Market

Sensex, Nifty Recover from Day's Low to End Higher; Maruti Suzuki Hits New High Post Q3 Results(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended higher.

Related Views on News

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

More Views on News

Most Popular

Tata Steel vs SAIL: Which Stock is Better?(Views On News)

Jan 13, 2022

With government initiatives set to boost the steel sector, find out who has a better chance of coming out on top.

These 5 Penny Stocks are Held by Rakesh Jhunjhunwala. Worth a Look?(Views On News)

Jan 18, 2022

Rakesh Jhunjhunwala is holding these penny stocks in his portfolio for several years now.

Tech Mahindra's CTC Acquisition: Too Expensive?(Views On News)

Jan 18, 2022

Tech Mahindra's acquisition of European IT-company fails to excite investors.

Time to Buy Energy Stocks(Fast Profits Daily)

Jan 14, 2022

Energy is a sector that looks set to take off. It's time to get in.

5 Hidden Tata Group Companies to Add to Your Watchlist(Views On News)

Jan 18, 2022

Here's all you need to know about these five Tata group stocks that aren't as popular as the others.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

KRSNAA DIAGNOSTICS SHARE PRICE


Jan 25, 2022 (Close)

TRACK KRSNAA DIAGNOSTICS

  • Track your investment in KRSNAA DIAGNOSTICS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON KRSNAA DIAGNOSTICS

KRSNAA DIAGNOSTICS 8-QTR ANALYSIS

COMPARE KRSNAA DIAGNOSTICS WITH

MARKET STATS